Dr. Monica Bertagnolli is the Richard Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School and an Associate Surgeon at Dana Farber/Brigham and Women’s Cancer Center (DF/BWCC). She is also a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at DF/BWCC, where she collaborates with colleagues in medical oncology, radiation oncology, and pathology to treat cancer patients in a tertiary care setting. Additionally, Dr. Bertagnolli was elected as the President of the American Society of Clinical Oncology and is currently serving her term from until June, 2019.
Dr. Bertagnolli graduated from Princeton University and attended medical school at the University of Utah. She trained in surgery at Brigham and Women’s Hospital and was a research fellow at the Dana Farber Cancer Institute. Dr. Bertagnolli’s laboratory work focuses on understanding the role of the inflammatory response in epithelial tumor formation. From 1994-2011, she led gastrointestinal correlative science initiatives within the NCI-funded Cancer Cooperative Groups, where she facilitated integration of tumor-specific molecular markers of treatment outcome into nation-wide clinical cancer treatment protocols. Dr. Bertagnolli has held numerous leadership roles in multi-institutional cancer clinical research consortia and currently serves as the Group Chair of the Alliance for Clinical Trials in Oncology, a new NCI-funded clinical trials group formed in 2011 by the merger of Cancer and Leukemia Group B; the North Central Cancer Treatment Group; and the American College of Surgeons Oncology Group. She is also the Chief Executive Officer of Alliance Foundation Trials, LLC, a not-for-profit corporation that conducts international cancer clinical trials.